Andere Sprachen MediciNova, Inc.

Aktien

A0LF3U

US58468P2065

MNOV

Realtime-Estimate Cboe BZX Andere Börsenplätze 17:12:45 20.06.2024			% 5 Tage	% 1. Jan.
1.3 ^USD	-0.76%		-5.61%	-13.79%

05.06.	MediciNova erhält Notice of Allowance für neues Patent auf MN-166 (Ibudilast) zur Vorbeugung von Metastasen bei verschiedenen soliden Krebsarten	CI
03.06.	MediciNova, Inc. gibt Daten aus der klinischen Phase 1B/2A-Studie mit Mn-166 (Ibudilast) bei Glioblastom-Patienten auf der Jahrestagung der American Society of Clinical Oncology (Asco) 2024 bekannt	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations	12:00
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 for the Prevention of Metastasis of Various Solid Cancer	06.06.
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer	05.06.
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer	05.06.
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 for the Prevention of Metastasis of Various Solid Cancer	05.06.
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024	03.06.
MediciNova, Inc. Announces Data from Phase 1B/2A Clinical Trial of Mn-166 in Glioblastoma Patients At the American Society of Clinical Oncology Annual Meeting 2024	03.06.
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 for Cardiometabolic Conditions	29.05.
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions	28.05.
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer	20.05.
MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 for the Prevention of Metastasis of Eye Cancer	20.05.
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome	14.05.
MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome	14.05.
MediciNova: Q1 Earnings Snapshot	10.05.
MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)	07.05.
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)	07.05.
MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166	07.05.
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting	03.04.
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)	03.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen MediciNova, Inc.

Aktien

A0LF3U

US58468P2065

MNOV

Andere Sprachen

Filter